• Corpus ID: 36425339

Chapter 2 Innovation in the Pharmaceutical Industry : The Process of Drug Discovery and Development

  title={Chapter 2 Innovation in the Pharmaceutical Industry : The Process of Drug Discovery and Development},
  author={Elina Petrova},
M. Ding et al. (eds.), Innovation and Marketing in the Pharmaceutical Industry, International Series in Quantitative Marketing 20, DOI 10.1007/978-1-4614-7801-0_2, © Springer Science+Business Media New York 2014 Abstract Continuous innovation is one of the pharmaceutical industry’s most defi ning characteristics. New medications can be crucial for maintaining the quality of human life, and may even affect its duration. The sales potential is staggering: the global pharmaceutical market is… 
1 Citations

Figures from this paper

Reforms in pharmaceuticals self-sufficiency in developing countries

Objectives: We explored several factors that could trigger domestic new drug development and incorporated them into a predictive model of an innovation policy. Method: We systematically searched the



Strategic Marketing Decision Models for the Pharmaceutical Industry

Given the importance of the pharmaceutical industry, strategic marketing decisions such as those relating to research and development (R&D), product management, market entry, growth, and reaction strategies are critical to the success of brands and firms in the industry.

Publicly Funded Science and the Productivity of the Pharmaceutical Industry

The impact of these huge expenditures on the technological performance of the pharmaceutical industry is evaluated and it is concluded that the returns from publicly funded research have been large, and may be growing even larger.

Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances

It is found that success probabilities vary substantially across therapeutic categories and are negatively correlated with mean sales by category, which is consistent with a model of dynamic, competitive entry.

The cost of biopharmaceutical R&D: is biotech different?

The results should be viewed with some caution for now given a limited number of biopharmaceutical molecules with data on cash outlays, different therapeutic class distributions for biophARMaceuticals and for pharmaceutical company drugs, and uncertainty about whether recent growth rates in pharmaceutical company costs are different from immediate past growth rates.

Rebuilding Big Pharma ’ s Business Model

The blockbuster business model that underpinned Big Pharma's success is now irreparably broken. The industry needs a new approach. I While the business climate for pharma companies has changed

Dynamic competition in pharmaceuticals

This paper investigates patterns of industrial dynamics and competition in the pharmaceutical industry, with particular reference to the consequences of patent expiry in different countries. We focus

Returns on Research and Development for 1990s New Drug Introductions

Examining the worldwide returns on R&D for drugs introduced into the US market in the first half of the 1990s reveals that a number of dynamic forces are currently at work in the industry, in particular,R&D costs as well as new drug introductions, sales and contribution margins increased significantly compared with their 1980s values.

Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act

IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting

Innovation and Strategic Divergence: An Empirical Study of the U.S. Pharmaceutical Industry from 1920 to 1960

This study empirically investigates the origin of this strategic divergence between some U.S. pharmaceutical firms responded to the opportunity presented by the discovery of antibiotics in the 1940s by investing more in R&D, while many others did not, and the gap between innovators and imitators steadily increased.